Clinical trial
A Phase I Study of FT819 in Subjects With B-cell Malignancies
NCT04629729 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of FT819 in Subjects With B-cell Malignancies
- Lead sponsor
- Fate Therapeutics
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- July 12, 2021
- Completion date
- September 30, 2039
- Enrollment
- 54 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia, lymphoma, b-cell, precursor b-cell acute lymphoblastic leukemia